Standard of care therapy for malignant glioma and its effect on tumor and stromal cells

Oncogene. 2012 Apr 19;31(16):1995-2006. doi: 10.1038/onc.2011.398. Epub 2011 Sep 12.


Glioblastoma is the most common and deadly of the primary central nervous system tumors. Recent advances in molecular characterization have subdivided these tumors into at least three main groups. In addition, these tumors are cellularly complex with multiple stromal cell types contributing to the biology of the tumor and treatment response. Because essentially all glioma patients are treated with radiation, various chemotherapies and steroids, the tumor that finally kills them has been modified by these treatments. Most of the investigation of the effects of therapy on these tumors has focused on the glioma cells per se. However, despite the importance of the stromal cells in these tumors, little has been done to understand the effects of treatment on stromal cells and their contribution to disease. Understanding how current standard therapy affects the biology of the tumor and the tumor stroma may provide insight into the mechanisms that are important to the inhibition of tumor growth as well as the biology of recurrent tumors.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / pathology*
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / therapy*
  • Glioma / drug therapy
  • Glioma / pathology*
  • Glioma / radiotherapy
  • Glioma / therapy*
  • Humans
  • Standard of Care
  • Stromal Cells / drug effects
  • Stromal Cells / pathology*
  • Stromal Cells / radiation effects